HUP9903921A2 - Tumor nekrózis faktorral rokon ligandum - Google Patents

Tumor nekrózis faktorral rokon ligandum

Info

Publication number
HUP9903921A2
HUP9903921A2 HU9903921A HUP9903921A HUP9903921A2 HU P9903921 A2 HUP9903921 A2 HU P9903921A2 HU 9903921 A HU9903921 A HU 9903921A HU P9903921 A HUP9903921 A HU P9903921A HU P9903921 A2 HUP9903921 A2 HU P9903921A2
Authority
HU
Hungary
Prior art keywords
trell
necrosis factor
protein
granulocyte
receptor
Prior art date
Application number
HU9903921A
Other languages
English (en)
Inventor
Jeffrey L. Browning
Yves Chicheportiche
Original Assignee
Biogen Inc.
The Faculty Of Medicine Of The University Of Geneva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc., The Faculty Of Medicine Of The University Of Geneva filed Critical Biogen Inc.
Publication of HUP9903921A2 publication Critical patent/HUP9903921A2/hu
Publication of HUP9903921A3 publication Critical patent/HUP9903921A3/hu
Publication of HU226787B1 publication Critical patent/HU226787B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

A találmány tárgyát tűmőrnekrózis faktőrral rőkőn ligandűm vagy TRELL,a tűmőrnekrózis faktőr család tagjai közé tartőzó pőlipeptid képezi. Afehérje vagy annak receptőra felhasználható rákellenes és/vagyimműnszabályőzó alkalmazásőkban. Tővábbá a TRELL-t kódőló génnelfertőzött sejtek felhasználhatók génterápiában daganatők, aűtőimműn ésgyűlladásős betegségek vagy öröklött genetikai rendellenességekkezelésére. A találmány tárgyát képezi a TRELL-fehérje, annakhőmőlógjai és biőlógiai aktivitással rendelkező fragmentűmai, valamintaz ezeket kódőló nűkleőtidszekvenciák. A TRELL-fehérje és receptőraellen termelhető antitestek szintén a találmány őltalmi körébetartőznak űgyanúgy, mint nevezett fehérjék őldható főrmáinakelőállítására alkalmas rekőmbináns gazdaszervezetek és nevezettfehérjéket, ill. azőkat kódőló nűkleinsavakat tartalmazógyógyszerkészítmények. ŕ
HU9903921A 1996-08-07 1997-08-07 A tumor necrosis factor related ligand HU226787B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2354196P 1996-08-07 1996-08-07
US2851596P 1996-10-18 1996-10-18
US4082097P 1997-03-18 1997-03-18
PCT/US1997/013945 WO1998005783A1 (en) 1996-08-07 1997-08-07 A tumor necrosis factor related ligand

Publications (3)

Publication Number Publication Date
HUP9903921A2 true HUP9903921A2 (hu) 2000-03-28
HUP9903921A3 HUP9903921A3 (en) 2000-08-28
HU226787B1 HU226787B1 (en) 2009-10-28

Family

ID=27362110

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9903921A HU226787B1 (en) 1996-08-07 1997-08-07 A tumor necrosis factor related ligand

Country Status (26)

Country Link
EP (2) EP1591530B8 (hu)
JP (3) JP4161084B2 (hu)
KR (1) KR100543730B1 (hu)
CN (2) CN101024831A (hu)
AT (1) ATE307204T1 (hu)
AU (1) AU736289B2 (hu)
BG (1) BG64779B1 (hu)
BR (1) BR9711046A (hu)
CA (1) CA2262756C (hu)
CZ (1) CZ297387B6 (hu)
DE (1) DE69734397T2 (hu)
DK (1) DK0956351T3 (hu)
EA (1) EA003187B1 (hu)
EE (1) EE05276B1 (hu)
ES (1) ES2251737T3 (hu)
HK (1) HK1025994A1 (hu)
HU (1) HU226787B1 (hu)
IL (1) IL128407A (hu)
IS (1) IS2606B (hu)
NO (2) NO326967B1 (hu)
NZ (1) NZ334107A (hu)
PL (1) PL188102B1 (hu)
SI (1) SI0956351T1 (hu)
SK (1) SK288012B6 (hu)
TR (1) TR199900903T2 (hu)
WO (1) WO1998005783A1 (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011791A2 (en) * 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
EP1967587A1 (en) * 1997-10-10 2008-09-10 Genentech, Inc. APO-3 Ligand
DE19829550C1 (de) * 1998-07-02 2000-01-27 Bosch Gmbh Robert Vorrichtung zum Verbinden von Bauteilen
JP5550799B2 (ja) * 1999-01-15 2014-07-16 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｔｗｅａｋのアンタゴニストおよびｔｗｅａｋレセプターのアンタゴニスト、ならびに免疫学的障害を処置するためのこれらの使用
CA2391530A1 (en) * 1999-11-19 2001-05-25 Thomas V. Tittle Tr3-specific binding agents and methods for their use
US6994976B1 (en) 1999-11-19 2006-02-07 Tittle Thomas V Tr3-specific binding agents and methods for their use
CA2394015C (en) * 1999-12-20 2013-11-05 Immunex Corporation Tweak receptor
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
US7495086B2 (en) 1999-12-20 2009-02-24 Immunex Corporation TWEAK receptor
CA2408228A1 (en) 2000-05-08 2001-11-15 Biogen, Inc. Method for promoting neovascularization
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
CN102793921A (zh) 2002-04-09 2012-11-28 比奥根艾迪克Ma公司 用于治疗tweak 相关病症的方法
CN101899106A (zh) * 2002-10-29 2010-12-01 阿纳福公司 三聚细胞因子的三聚结合蛋白
EP2332408B1 (en) 2005-02-17 2013-11-13 Biogen Idec MA Inc. Treating neurological disorders
ES2432564T3 (es) 2005-05-10 2013-12-04 Biogen Idec Ma Inc. Tratamiento y evaluación de trastornos inflamatorios
ES2507069T3 (es) 2005-05-27 2014-10-14 Biogen Idec Ma Inc. Anticuerpos de unión a TWEAK
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
EA201300418A1 (ru) 2010-10-05 2013-09-30 Ф.Хоффманн-Ля Рош Аг Антитела к человеческому tweak и варианты их применения
AU2013244999A1 (en) 2012-04-05 2014-09-25 F. Hoffmann-La Roche Ag Bispecific antibodies against human TWEAK and human IL17 and uses thereof
CN110023499A (zh) * 2016-10-24 2019-07-16 拜欧亿思有限公司 肿瘤坏死因子-α(TNF-α)结合适配体及其治疗用途
WO2019203904A1 (en) * 2018-04-20 2019-10-24 Academia Sinica Tnf-targeting aptamers and uses thereof for treatment or diagnosing tnf-related inflammatory diseases
WO2022217283A1 (en) 2021-04-08 2022-10-13 Joslin Diabetes Center, Inc. Methods of diagnosing and predicting renal decline

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
IE902820A1 (en) 1989-08-07 1991-02-27 Merck & Co Inc Peptide inhibitors of human papilloma virus protein binding¹to retinoblastoma gene proteins
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
CA2077322A1 (en) 1991-09-04 1993-03-05 Allen I. Oliff Peptide inhibitors of human papilloma virus protein binding to retinoblastoma gene proteins

Also Published As

Publication number Publication date
AU3829497A (en) 1998-02-25
JP2001505407A (ja) 2001-04-24
CN1232503A (zh) 1999-10-20
CN101024831A (zh) 2007-08-29
WO1998005783A1 (en) 1998-02-12
EP0956351B1 (en) 2005-10-19
JP2007204480A (ja) 2007-08-16
SK288012B6 (sk) 2012-10-02
IL128407A (en) 2007-07-24
AU736289B2 (en) 2001-07-26
DK0956351T3 (da) 2006-02-20
EP1591530B1 (en) 2015-02-25
JP2009183294A (ja) 2009-08-20
SK15799A3 (en) 2000-03-13
KR100543730B1 (ko) 2006-01-23
DE69734397T2 (de) 2006-07-06
TR199900903T2 (xx) 1999-06-21
NO20084906L (no) 1999-04-06
DE69734397D1 (de) 2006-03-02
KR20000029877A (ko) 2000-05-25
IS2606B (is) 2010-04-15
NO990550L (no) 1999-04-06
JP4161084B2 (ja) 2008-10-08
PL188102B1 (pl) 2004-12-31
PL331583A1 (en) 1999-07-19
CN1308451C (zh) 2007-04-04
CA2262756A1 (en) 1998-02-12
EE9900043A (et) 1999-08-16
HUP9903921A3 (en) 2000-08-28
SI0956351T1 (sl) 2006-02-28
NO990550D0 (no) 1999-02-05
CA2262756C (en) 2012-06-12
HK1025994A1 (en) 2000-12-01
EP1591530B8 (en) 2015-04-22
EE05276B1 (et) 2010-02-15
BG64779B1 (bg) 2006-03-31
EA199900187A1 (ru) 1999-08-26
HU226787B1 (en) 2009-10-28
CZ40399A3 (cs) 1999-08-11
EP1591530A2 (en) 2005-11-02
JP4411330B2 (ja) 2010-02-10
NO326967B1 (no) 2009-03-23
EP0956351A1 (en) 1999-11-17
EP1591530A3 (en) 2009-04-08
ATE307204T1 (de) 2005-11-15
EA003187B1 (ru) 2003-02-27
CZ297387B6 (cs) 2006-11-15
BR9711046A (pt) 2000-01-11
NZ334107A (en) 2000-06-23
ES2251737T3 (es) 2006-05-01
IS4967A (is) 1999-02-05
IL128407A0 (en) 2000-01-31
BG103169A (en) 2000-06-30

Similar Documents

Publication Publication Date Title
HUP9903921A2 (hu) Tumor nekrózis faktorral rokon ligandum
NL990033I2 (nl) Tumornecrosefactor, werkwijzen om het te bereiden,samenstellingen die het bevatten, DNA dat ervoor codeert en proefmethoden met degelijk DNA.
HUP0500345A2 (hu) Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
MY101852A (en) Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna.
BG100771A (en) Hematopoeic protein and ways and methods for its preparation
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
AU539535B2 (en) Recombinant dna molecules
BR0316435A (pt) Produtos genéticos expressos diferencialmente em tumores e uso dos mesmos
DK1240325T3 (da) IL-17 og IL-17R homologe polypeptider og terapeutisk anvendelse deraf
WO2000055345A3 (en) Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
WO2001057182A3 (en) Nucleic acids, proteins, and antibodies
MXPA02000192A (es) Composiciones y metodos para la terapia y diagnostico de cancer de pulmon.
HUP0101948A2 (hu) Il-2-szelektív agonisták és antagonisták
HUP0202882A2 (en) Novel b7-4 molecules and uses therefor
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
DK0961831T3 (da) Humant alfa-endokin
ATE229977T1 (de) Peptide mit antiproliferativen eigenschaften
ATE71632T1 (de) Cdns und gen fuer menschliches angiogenin (angiogenesis-faktor) und expression.
DE3856180D1 (de) Nukleinsaürefragmente, die mannose bindende fragmente vom menschlichen mannosebindenden protein kodieren
IT1298487B1 (it) Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
WO2002088750A3 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
ES2168361T3 (es) Secuencias de adn para metaloproteasas de la matriz, su preparacion y empleo.
DE60039677D1 (de) Akt-3 nukleinsäure, polypeptide und deren verwendung
WO2005026205A3 (de) Differentiell in tumoren exprimierte genprodukte und deren verwendung

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: THE FACULTY OF MEDICINE OF THE UNIVERSITY OF G, CH

Free format text: FORMER OWNER(S): BIOGEN INC., US

Owner name: BIOGEN IDEC MA INC., US

Free format text: FORMER OWNER(S): BIOGEN INC., US